You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Nilotinib – Differentiating the Hope from the Hype

Abstract

We discuss a report in the current issue on clinical and biochemical findings from a safety trial using the cAbl tyrosine kinase inhibitor Nilotinib (150 mg or 300 mg given daily for 24 weeks) in a small group of patients with either advanced Parkinson’s disease or Dementia with Lewy Bodies. Despite some side effects (one serious), the authors claim that Nilotinib, which is normally used at much higher doses for treating leukemia, is safe and tolerated. Furthermore, they report a possible benefit on motor and cognitive outcomes. We debate the safety of Nilotinib and the reported efficacy signals. We emphasize that due to the small sample size, and lack of a control group, it is impossible to rule out a placebo effect. We briefly discuss a range of aspects surrounding the current and possible future use of this cAbl inhibitor in patients with alpha-synucleinopathy, and what must now be done to obtain definitive information about its safety and efficacy in this population of patients.

MAIN TEXT

The paper by Pagan et al. [1], published in this issue, was originally reported as a brief abstract at the Society for Neuroscience in Chicago in October 2015. The world’s press and television news channels gave high coverage to this abstract, with some of the study patients shown worldwide in videos that focused on their purported clinical improvements. Many neurology experts felt that the global media exposure which followed the initial announcement of the results was an object lesson on how not to report a small clinical trial that has no placebo control. While patients suffering from Parkinson’s disease (PD) and related alpha-synucleinopathies continue to feel an urgent need for better therapies, this news story inappropriately fed their hope with hype. Following the global news story, the authors of this editorial were made aware that the off label use of Nilotinib in PD escalated. It is currently conservatively estimated that >200 PD patients across many countries are taking Nilotinib. Not only is Nilotinib extremely expensive, but it carries a black box warning at its leukemia doses and its safety at low doses in PD and has only been studied in the 12 patients suffering from PD or Dementia with Lewy Bodies (DLB) in the current trial. Unfortunately some side effects were noted amongst the 12 patients within the 6 month study period [1]. Therefore, definitive proof is now required, one way or the other and as quickly as possible, as to whether Nilotinib is safe in PD and DLB, and whether the hints of possible improvement are apparent in a larger group of patients when compared to placebo.

Nilotinib is a brain penetrant tyrosine kinase cAbl inhibitor used for the treatment of chronic myeloid leukemia. It is approved for this condition at doses up to 1200 mg daily (EU) and up to 800 mg daily (USA) where it carries a black box warning for QT interval prolongation; sudden cardiac death has been reported in patients taking Nilotinib, and it can also cause myelosuppression. One patient of the twelve in the study had a serious cardiac event during the 6 month duration of the study, although the investigators felt it was partially related to an initial electrocardiogram (ECG) screening failure [1]. Two other patients in the study had QT prolongation. Emerging ECG abnormalities such as these occur in a considerable number of leukemia patients taking Nilotinib at the oncology doses [2, 3], and these can lead to fatal cardiac events. Taken together, these facts indicate a study reporting on the safety of Nilotinib in a small patient cohort during 6 months should be interpreted with caution. Pagan and collaborators had selected a group of advanced and relatively frail PD and DLB patients for their trial. Why this patient group was targeted is not clear, and indeed in the listing for this trial on the clinicaltrials.gov website it specifies that patients would be at Hoehn and Yahr stage <2 as an inclusion criterion [4]. Selecting these later stage patients generated a large number of screen failures but, paradoxically, may have helpfully given a tougher test of the safety and tolerability issues surrounding the use of low dose Nilotinib.

Preclinical studies had strongly suggested that cAbl inhibition by Nilotinib might interfere with pathogenic mechanisms that are relevant to PD and DLB and therefore could potentially modify the course of these diseases [5– 16]. The biochemical basis for this hypothesis has multiple threads. cAbl is substantially activated (by phosphorylation) in brains of PD patients, as well as in MPTP and in alpha-synuclein preclinical models of PD. cAbl phosphorylation appears to be a consequence of mitochondrial dysfunction [17]. cAbl activation by phosphorylation is highly indicative of increased oxidative stress, and in dopaminergic neurons this is thought to contribute to the pathogenesis of PD. cAbl inhibition by Nilotinib has been shown both to protect against MPTP damage, and to reduce intracellular levels of alpha-synuclein by autophagic degradation. Also, given it is widely reported that Parkin function is compromised in sporadic PD, the observation that Nilotinib can also act as a Parkin agonist by preventing its phosphorylation also represents yet another important putative mode of action. By inhibiting the phosphorylation of Parkin, Nilotinib may well offer protection against alpha-synuclein toxicity through a cytoprotective process that would be consistent with observations that overexpression of Parkin protects against the effects of α-synuclein-induced toxicity [18]. In addition, there is evidence that some parallel Parkin-independent benefits of cAbl inhibition may also be clinically relevant [5].

In 2012, and again in 2013, an international committee of PD experts discussed in great detail the preclinical evidence for taking Nilotinib into a clinical trial in PD patients [19]. At the time, it was questioned whether a low, and potentially safer, dose of Nilotinib might be appropriate to test in PD. The conclusion was that, while the biological target (cAbl inhibition) is highly relevant in PD, given potential safety issues with Nilotinib it was not given top priority as a drug repurposing candidate [19]. Thus, the study reported in this issue became the first in-human testing of Nilotinib in patients with alpha-synucleinopathies. The daily doses of 150 mg and 300 mg of Nilotinib produced some adverse events, but helpfully opened the door on a lower dose range that might be appropriate to consider in the future definitive trial(s) of Nilotinib. The choice of these doses was not arbitrary; preclinical research would suggest efficacy in alpha-synuclein models at even lower doses than this, but Nilotinib is only available in capsules of 150 mg minimum size and it is impractical to divide these. Future PD trials involving Nilotinib will have to determine if this is an optimal dose in PD and DLB.

The value of measuring cerebrospinal fluid (CSF) levels of the dopamine metabolite homovanillic acid (HVA), as reported in this study, is unclear. Prior studies suggest that HVA levels in CSF vary greatly between patients at similar disease stages and track poorly with disease progression. Similarly, CSF levels of S100B and neuron-specific enolase (NSE), also used in the current study and which correlate with damage to neurons and glia, respectively, in stroke and in spinal & intracranial injuries, are not validated biomarkers for PD and DLB [20– 22]. Finally, the changes or lack of changes in alpha-synuclein measures in the study are difficult to interpret given our current understanding of the different molecular forms of this protein and their relation to disease progression [23]. In short, substantial caution should be exercised when interpreting changes in CSF levels of HVA, S100B, NSE and alpha-synuclein.

So, what can we take from this small but innovative study? Given the publicity surrounding the trial when it was initially announced, it is important (as published in this issue) to have the full results of this trial made widely available to the scientific community. But it is impossible to extract definitive safety and valid efficacy signals from a small open-label unblinded study (lacking a placebo control) in PD and DLB. This is especially poignant as even a placebo effect can be very large over the time period used in this study, particularly in advanced PD [24], and can even induce biochemical changes in the dopamine system [25, 26].

Perhaps the most important conclusions to be drawn from this study are that:

  • 1) A future double-blinded study is definitely warranted. Given the importance of the next clinical study evaluating Nilotinib, we encourage the involvement of leaders in PD clinical trial design and the use of well-established multi-site clinical study protocols. All raw data from any future study should be made widely available to the research and patient communities to allow detailed evaluation without any restrictions.

  • 2) The current study also helpfully gives us a first clue as to what dose(s) of Nilotinib might offer a sensible balance between safety concerns and the search for efficacy. As future definitive trials are designed, there is a need further to consider the most appropriate dose and also to determine which PD patients are most likely to benefit from this type of therapeutic approach.

In conclusion, the current paper by Pagan et al. substantiates a new direction, addressing a molecular pathway not previously targeted in a clinical trial in this context, for potential disease modification in PD and DLB. However, this study is just a first step and a major concerted effort is needed to determine whether there is still hope that can match the hype for Nilotinib in alpha-synucleinopathies.

DISCLOSURES

RW   None.

PB Dr. Brundin has received commercial support as a consultant from Renovo Neural, Inc., Roche, Teva Pharmaceutical Industries, Lundbeck A/S, AbbVie Inc, ClearView Healthcare, FCB Health, IOS Press Partners and Capital Technologies, Inc. Additionally he has received commercial support for grants/research from Renovo Neural Inc, Teva Pharmaceutical Industries and Lundbeck A/S. Dr. Brundin has ownership interests in Acousort AB and Parkcell AB.

TS   None.

REFERENCES

[1] 

Pagan F , Hebron M , Valadez EH , Tores-Yaghi Y , Huang X , Mills RR , Wilmarth BM , Howard H , Dunn C , Carlson A , Lawler A , Rogers SL , Falconer R , Ahn J , Li Z , & Moussa C (2016) Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies. J Parkinsons Dis.

[2] 

Moslehi JJ , & Deinenger M (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33, 4210–4218.

[3] 

Stève-Dumont M , Baldin B , Legros L , Thyss A , Re D , Rocher F , Ajmia F , Spreux A , & Drici MD (2015) Are nilotinib-associated vascular adverse events an under-estimated problem?. Fundam Clin Pharmacol 29, 204–208.

[4] 

ClinicalTrials.gov. Nilotinib in Cognitively Impaired Parkinson Disease Patients 001, https://clinicaltrials.gov/show/NCT02281474

[5] 

Karuppagounder SS , Brahmachari SK , Lee Y , Dawson VL , Dawson TM , & Han Seok Ko (2014) The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep 4, 4874.

[6] 

Ko HS , Lee Y , Shin JH , Karuppagounder SS , Gadad BS , Koleske AJ , Pletnikova O , Troncoso JC , Dawson VL , & Dawson TM (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci U S A 107, 16691–16696.

[7] 

Schlatterer SD , Acker CM , & Davies P (2011) c-Abl in neurodegenerative disease. J Mol Neurosci 45, 445–452.

[8] 

Imam SZ , Zhou Q , Yamamoto A , Valente AJ , Ali SF , Bains M , Roberts JL , Kahle PJ , Clark RA , & Li S (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson’s disease. J Neurosci 31, 157–163.

[9] 

Hebron ML , Lonskaya I , & Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson’s disease models. Hum Mol Genet 22, 3315–3328.

[10] 

Lonskaya I , Hebron ML , Desforges NM , Schachter JB , & Moussa CE (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl) 92, 373–386.

[11] 

Imam SZ , Trickler W , Kimura S , Binienda ZK , Paule MG , Slikker W Jr , Clark RA , & Ali SF (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson’s disease model. PLoS One 8, e65129.

[12] 

Hebron ML , Lonskaya I , & Moussa C (2013) Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance. Autophagy 9, 1249–1250.

[13] 

Hebron ML , Lonskaya I , Olopade P , Selby ST , Pagan F , & Moussa CE (2014) Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in α-synucleinopathy. J Clin Cell Immunol 5, 259.

[14] 

Mahul-Mellier AL , Fauvet B , Gysbers A , Dikiy I , Oueslati A , Georgeon S , Lamontanara AJ , Bisquertt A , Eliezer D , Masliah E , Halliday G , Hantschel O , & Lashuel HA (2014) c-Abl phosphorylates alpha-syn and regulates its degradation, implication foralpha-syn clearance and contribution to the pathogenesis of Parkinson’s Disease. Hum Mol Genet 23, 2858–2879.

[15] 

Tanabe A , Yamamura Y , Kasahara J , Morigari R , Kaji R , & Goto S (2014) A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease. Front Cell Neurosci 8, 50.

[16] 

Brahmachari S , Ge P , Lee SH , Kim D , Karuppagounder SS , Kumar M , Mao X , Lee Y , Pletnikova O , Troncoso JC , Dawson VL , Dawson TM , & Ko HS (2016) . Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest. doi: 10.1172/JCI85456

[17] 

Dawson TM , & Dawson VL (2014) Parkin plays a role in sporadic Parkinson’s disease. Neurodegener Dis 13, 69–71.

[18] 

Petrucelli L , O’Farrell C , Lockhart PJ , Baptista M , Kehoe K , Vink L , Choi P , Wolozin B , Marrer M , Hardy J , & Cookson MR (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007–1019.

[19] 

Brundin P , Barker RA , Conn PJ , Dawson TM , Kieburtz K , Lees AJ , Schwarzschild MA , Tanner CM , Isaacs T , Duffen J , Matthews H , & Wyse RK (2013) Linked clinical trials–the development of new clinical learning studies in Parkinson’s disease using screening of multiple prospective new treatments. J Parkinsons Dis 3, 231–239.

[20] 

Manzano S , Holzinger IB , Kellenberger CJ , Lacroix L , Klima-Lange D , Hersberger M , La Scala G , Altermatt S , & Staubli G (2016) Diagnostic performance of S100B protein serum measurement in detecting intracranial injury in children with mild head trauma. Emerg Med J 33, 42–46.

[21] 

Wolf H , Krall C , Paienda G , Leitgeb J , Bukaty AJ , Hadju S , & Sarahrudi K (2014) Alterations of the biomarker S-100B and NSE in patients with acute vertebral spine fractures. Spine J 14, 2918–2922.

[22] 

Tolan NV , Vidal-Folch N , Algeciras-Schimnich A , Singh RJ , & Grebe SK (2013) Individualized correction of neuron-specific enolase (NSE) measurement in hemolyzed serum samples. Clin Chim Acta 424, 216–221.

[23] 

Hong Z , Shi M , Chung KA , Quinn JF , Peskind ER , Galasko D , Jankovic J , Zabetian CP , Leverenz JB , Baird G , Montine TJ , Hancock AM , Hwang H , Pan C , Bradner J , Kang UJ , Jensen PH , & Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133, 713–726.

[24] 

Diederich NJ , & Goetz CG (2008) The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology 71, 677–684.

[25] 

Benedetti F , Colloca L , Torre E , Lanotte M , Melcarne A , Pesare M , Bergamasco B , & Lopiano L (2004) Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 7, 587–588.

[26] 

de la Fuente-Fernandez R , Ruth TJ , Sossi V , Schulzer M , Calne DB , & Stoessl AJ (2001) Expectation and dopamine release: Mechanism of the placebo effect in Parkinson’s disease. Science 293, 1164–1166.